Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids

Streuli, Isabelle; Fraisse, Timothée; Pillet, Christine; Ibéchéole, Victoria; Bischof, P.; Ziegler, Dominique de

doi:10.1016/j.fertnstert.2007.06.023

Cited by 237 publications

(172 citation statements)

References 8 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…In this respect, various results have been reported regarding the impact of steroid suppression on serum AMH levels. Some studies reported null effect of OCP treatment on serum AMH levels [18,21,22], whereas others revealed suppressed AMH levels in normal cycling women pretreated with OCP [1,15]. In a recent case report it was demonstrated that during 16 week course of menotropin treatment both serum AMH and AFC increased in an IHH patient.…”

Section: Discussionmentioning

confidence: 99%

Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

Sönmezer

Özmen

Atabekoglu

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The role of serum AMH levels in prediction of ovarian response in idiopathic hypogonadotropic hypogonadism (IHH) was evaluated. Material method(s) Twelve patients with IHH underwent controlled ovarian hyperstimulation (COH) for IVF were enrolled in this prospective study. Serum AMH levels were studied on the 2nd or 3rd day of an induced menstrual cycle by a preceding low-dose oral contraceptive pill treatment. A fixed dose (150-300 IU/day) of hMG was given in all COH cycles. Correlations between serum AMH levels, COH outcomes and embryological data were investigated. Results Mean serum AMH levels was 3.47±2.15 ng/mL and mean serum peak estradiol was 2196±1705 pg/mL. Mean number of follicles >14 mm, >17 mm on hCG day and MII oocytes were 4.14±3.2, 4±2.5 and 7.28±3.5, respectively. Mean number of grade A embryos and transferred embryos were 3.28 ± 2.4 and 2.5 ± 0.7, respectively. The clinical pregnancy rate per patient was 41.6 % (5/12). Positive correlations were observed between serum AMH levels and MII oocytes (r00.84), grade A embryos (r00.85), serum peak estradiol levels (r00.87), and number of follicles >14 mm (r00.83) and >17 mm (r00.81) on hCG day, respectively. Conclusion AMH appears as a promising marker of ovarian response in patients with IHH undergoing IVF.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

Sönmezer

Özmen

Atabekoglu

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Controversies exist with regard to the effect of OC-use on serum AMH levels. Some studies showed that exogenous sex steroids did not affect AMH levels (27), whereas others did find an effect of OC-use (23, 28). In our study, the effect of OC-use on AMH levels remained significant, even after stepwise correction for age, gestational age, BL SDS, BW SDS, adult height SDS, FM, age at menarche, SES, smoking, alcohol use and maternal smoking during gestation.…”

Section: Discussionmentioning

confidence: 99%

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Kerkhof

Leunissen

Willemsen

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Background/objectives: Preterm birth has been associated with reduced reproduction rates, and controversies remain regarding the effect of being born small for gestational age (SGA) on ovarian function. Recent findings in young men showed no effect of preterm and SGA birth on testis function. We hypothesised that follicle pool size in young adult women is also not affected by preterm and SGA birth. Design/methods: In 279 young women of the PROGRAM/PREMS study, aged 18-24 years, the influence of gestational age, birth length and birth weight on serum levels of anti-Mü llerian hormone (AMH) was analysed with multiple regression modelling. Additionally, AMH levels were analysed in preterm-versus term-born females and in three subgroups: females born SGA with either short stature or catch-up growth (SGA-CU), and females born term and appropriate for gestational age with normal stature (AGA controls). Results: Preterm and SGA birth did not affect AMH and other hormone levels. Older age at menarche and oral contraceptive pill use (OC-use) were related to lower AMH levels, and maternal smoking during gestation was related to higher AMH levels. After correction for maternal smoking, lower socioeconomic status (SES) was associated with lower AMH levels. In subgroup comparisons, SGA-CU women showed higher AMH levels than AGA controls, also after adjustment for several factors. Conclusion: Preterm and SGA birth did not affect AMH levels. Factors associated with serum AMH levels were OC-use, age at menarche, maternal smoking during gestation and SES. We conclude that preterm-and/or SGA-born females are not likely to have a reduced follicle pool size.

show abstract

“…Indeed, AMH levels are stable across the menstrual cycle and are not affected by pregnancy or treatment with gonadotropinreleasing hormone agonists. In addition, although an effect of combined oral contraceptive pill on ovarian reserve has been described (Bentzen et al 2012, Deb et al 2012, Kallio et al 2013, its use seems to be associated with minimal suppression of the later FSH-dependent stages of follicle development (Arbo et al 2007, Streuli et al 2008, Sowers et al 2010, Li et al 2011, Shaw et al 2011. It is still debated if clinical and behavioral variables, such as BMI and smoking habit, may influence AMH plasma levels.…”

Section: Amh and Fertilitymentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids

Cited by 237 publications

References 8 publications

Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism

Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Contact Info

Product

Resources

About